Akari Therapeutics ($AKTX) is a biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer.
Joined March 2018
- Tweets476
- Following114
- Followers366
- Likes67
In the latest CEO Corner, $AKTX CEO Abizer Gaslightwala discusses Akari’s differentiated ADC payload strategy, growing industry interest in novel payload technologies and progress advancing AKTX-101 toward planned Phase 1 clinical development in mid-2027
vimeo.com/1235949757/cddfa2c…
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
bit.ly/4dzXhJq
$AKTX #Oncology #ADCS #AntibodyDrugConjugates
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
bit.ly/4dCOt5z
$AKTX #Oncology #ADCS #AntibodyDrugConjugates
$AKTX will be at World ADC San Diego, October 12–15!
We look forward to connecting with industry leaders and discussing the latest developments across the ADC landscape.
Interested in meeting with the Akari team? Email [email protected] to schedule a meeting.
#ADC #Oncology
Did you see our H.C. Wainwright fireside chat?
Hear from $AKTX management on our novel PH1 payload platform, the advancement of AKTX-101 and our broader strategy for next-generation ADC development.
Watch on-demand: bit.ly/3VmRbFR
#ADC #Oncology
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
bit.ly/47viW1I
$AKTX #Oncology #ADCS #AntibodyDrugConjugates
Akari Therapeutics is pleased to attend the ROTH 5th Annual Healthcare Opportunities Conference on September 29 in New York City.
We look forward to connecting with investors and industry leaders at this year’s event.
$AKTX #Oncology #ADC #CancerResearch
#InCaseYouMissedIt: Our on-demand fireside chat for the H.C. Wainwright 28th Annual Global Investment Conference is now available!
Check it out here: bit.ly/4dl6CEv
$AKTX #ADC #Oncology #CancerResearch
Receive the latest on Akari Therapeutics straight from the source.
Subscribe to our email alerts for direct access to company news, press releases and important updates as they’re announced.
Sign up: bit.ly/42qsMAz
$AKTX #Oncology #ADC #CancerResearch
$AKTX CEO Abizer Gaslightwala will speak at the 2026 Global XDC Innovation Conference, taking place September 17–19 in Wuxi, China.
Learn more: bit.ly/4xrCgbD
#ADC #Oncology #CancerResearch
$AKTX is heading to BioCon China Expo 2026!
CEO Abizer Gaslightwala will join biopharma leaders at the 13th International Biopharmaceutical R&D Convention to share insights and perspectives on innovation shaping the industry.
Learn more: bit.ly/4idrXTO
$AKTX CEO Abizer Gaslightwala joined an expert panel at the Oncology & Immunology Innovation Partnering & Licensing Summit to discuss novel payload strategies and translating ADC innovation into clinical success.
#ADC #Oncology #CancerResearch
We will be in New York City for the H.C. Wainwright 28th Annual Global Investment Conference happening September 14–16.
Looking forward to connecting with companies and investors from across the healthcare sector.
$AKTX #ADC #Oncology #CancerResearch
$AKTX CEO Abizer Gaslightwala will join an expert panel at the Oncology & Immunology Innovation Partnering & Licensing Summit on September 10 to discuss novel ADC payload strategies and advancing innovation toward the clinic.
#ADC #Oncology #CancerResearch
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
bit.ly/4idrXTO
$AKTX #Oncology #ADCS #AntibodyDrugConjugates
#InCaseYouMissedIt: Our CEO, Abizer Gaslightwala, reflects on the Company’s strategic progress and path toward clinical development, including the advancement of AKTX-101 and expansion of its novel ADC pipeline.
Watch the latest CEO Corner: bit.ly/47lHKJh
$AKTX #ADC